World's Best Scientists 2026 revealed!
Masatoshi Kudo

Masatoshi Kudo

Award Badge
Medicine
Japan
2023

D-Index & Metrics

Medicine

D-Index
147
Citations
120253
World Ranking
1252
National Ranking
21

Research.com Recognitions

  • 2023 - Research.com Medicine in Japan Leader Award

Overview

Masatoshi Kudo is affiliated with Kindai University in Japan and has a significant presence in the field of medicine, with a primary focus on hepatology and oncology. Their research contributions encompass a wide range of topics including hepatocellular carcinoma treatment and prognosis, liver disease diagnosis and treatment, pancreatic and hepatic oncology research, cancer immunotherapy and biomarkers, colorectal cancer treatments and studies, cholangiocarcinoma and gallbladder cancer studies, as well as cancer mechanisms and therapy.

Their frequent co-authors include Naoshi Nishida, Richard S. Finn, Masafumi Ikeda, Kosuke Minaga, and Ann-Lii Cheng, indicating collaborative work within the hepatology and oncology research communities.

The scientist's research has been published extensively in several prominent venues, notably:

  • Liver Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepatology
  • Hepatology Research

Some of their recent papers include:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020), published in New England Journal of Medicine
  • Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021), published in Journal of Hepatology
  • Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022), published in NEJM Evidence
  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020), published in JAMA Oncology
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020), published in Journal of Clinical Oncology

Kudo's subfields of study include hepatology with 449 publications, oncology with 307 publications, epidemiology with 194, surgery with 170, and pulmonary and respiratory medicine with 150 publications, reflecting a broad interdisciplinary approach within medical research.

The main field of study identified for this scientist is medicine, with a total of 1461 publications attributed to that field. This indicates a broad and sustained engagement with clinical and biomedical research over time.

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

    Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

    Michel Claudon;Christoph F. Dietrich;Byung Ihn Choi;David O. Cosgrove

  • Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - Update 2012

    M. Claudon;C. F. Dietrich;B. I. Choi;D. O. Cosgrove

  • Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

    Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister;Dominik Pfister;Nicolás Gonzalo Núñez;Roser Pinyol;Olivier Govaere

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study

    Joong Won Park;Minshan Chen;Massimo Colombo;Lewis Rowland Roberts

  • Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

    Masatoshi Kudo;Namiki Izumi;Norihiro Kokudo;Osamu Matsui

  • WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology.

    Tsuyoshi Shiina;Kathryn R. Nightingale;Mark L. Palmeri;Timothy J. Hall

  • Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

    Jordi Bruix;Tadatoshi Takayama;Vincenzo Mazzaferro;Gar Yang Chau

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

    Masatoshi Kudo;Hobyung Chung;Yukio Osaki

Frequent Co-Authors

Andrew X. Zhu
Andrew X. Zhu Harvard University
Namiki Izumi
Namiki Izumi Musashino Red Cross Hospital
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Takuji Okusaka
Takuji Okusaka National Cancer Centre
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Norihiro Kokudo
Norihiro Kokudo National Center For Global Health and Medicine
Josep M. Llovet
Josep M. Llovet University of Barcelona
Michiie Sakamoto
Michiie Sakamoto Keio University
Takamichi Murakami
Takamichi Murakami Kobe University
Tadatoshi Takayama
Tadatoshi Takayama Nihon University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA goes beyond the traditional MD. Many students and professionals seek flexible online options that support their career growth or allow for a smoother transition into healthcare leadership roles.

For working adults looking to advance in healthcare management, finding whats the best online mha program for working adults is essential. These programs let you balance work and study, offering accredited pathways to become a healthcare administrator.

Nursing professionals interested in furthering their education may consider rn bsn online programs no clinicals for an efficient route to a bachelor's degree. These options are perfect for those seeking academic progression without additional clinical hours.

If advancing into clinical practice or leadership, you might prefer the fastest msn to dnp program—ideal for nurses wanting to earn a Doctor of Nursing Practice in the shortest time possible. For even more convenience, there are dnp online programs designed for flexibility and accessibility, allowing nurses to reach the highest level of practice without disrupting their careers.

Best Scientists Citing Masatoshi Kudo

Trending Scientists

Recently Published Articles